Cargando…

Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma

BACKGROUND: Enhancer of zesta homologue 2 (EZH2) is an essential component of polycomb repressive complex 2 (PRC2) that contributes to tumor progression and chemo-resistance. The aim of this study was to comprehensively assess the prognostic value of EZH2 across the morphologic and molecular spectra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reid, Brett M., Vyas, Shraddha, Chen, Zhihua, Chen, Ann, Kanetsky, Peter A., Permuth, Jennifer B., Sellers, Thomas A., Saglam, Ozlen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212453/ https://www.ncbi.nlm.nih.gov/pubmed/34140011 http://dx.doi.org/10.1186/s12885-021-08413-3

Ejemplares similares

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Epidemiology of ovarian cancer: a review
por: Reid, Brett M., et al.
Publicado: (2017)

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2019)

Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer
por: Criscuolo, Daniela, et al.
Publicado: (2022)

Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon
por: Abdallah, Reem, et al.
Publicado: (2023)

Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients
por: Li, Yuan, et al.
Publicado: (2021)

Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status
por: Li, Yongmei, et al.
Publicado: (2022)

Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer
por: Ganapathi, Ram N., et al.
Publicado: (2020)

Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2020)

Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
por: Hwangbo, Suhyun, et al.
Publicado: (2021)

Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer
por: Tan, Jiahong, et al.
Publicado: (2021)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Low Grade Ovarian Serous Carcinoma - A Clinical-Morphologic Study
por: DOCHIȚ, C, et al.
Publicado: (2019)

Digital Pathology-based Study of Cell- and Tissue-level Morphologic Features in Serous Borderline Ovarian Tumor and High-grade Serous Ovarian Cancer
por: Jiang, Jun, et al.
Publicado: (2021)

Modeling Platinum Sensitive and Resistant High-Grade Serous Ovarian Cancer: Development and Applications of Experimental Systems
por: Cunnea, Paula, et al.
Publicado: (2014)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer
por: Silva, Vera L., et al.
Publicado: (2021)

Pathogenic Heteroplasmic Somatic Mitochondrial DNA Mutation Confers Platinum-Resistance and Recurrence of High-Grade Serous Ovarian Cancer
por: Ni, Jing, et al.
Publicado: (2020)

Precursor Lesions of High-Grade Serous Ovarian Carcinoma: Morphological and Molecular Characteristics
por: Gross, Amy L., et al.
Publicado: (2010)

Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics
por: Handley, Katelyn F., et al.
Publicado: (2022)

Highly Expressed Progesterone Receptor B Isoform Increases Platinum Sensitivity and Survival of Ovarian High-Grade Serous Carcinoma
por: Lin, Hao, et al.
Publicado: (2021)

Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
por: Spiliopoulou, Pavlina, et al.
Publicado: (2022)

Metabolism of Estrogens: Turnover Differs between Platinum-Sensitive and -Resistant High-Grade Serous Ovarian Cancer Cells
por: Poschner, Stefan, et al.
Publicado: (2020)

SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer
por: Winkler, Claudia, et al.
Publicado: (2021)

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
por: Feng, Zheng, et al.
Publicado: (2023)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Seven Genes Based Novel Signature Predicts Clinical Outcome and Platinum Sensitivity of High Grade IIIc Serous Ovarian Carcinoma
por: Liu, Gang, et al.
Publicado: (2018)

Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients
por: Mignogna, Chiara, et al.
Publicado: (2016)

The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma
por: Stronach, Euan A., et al.
Publicado: (2015)

Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer
por: Tomar, Tushar, et al.
Publicado: (2017)

3468 Predictive biomarkers of platinum-based chemotherapy response in Puerto Rican Hispanics with high-grade serous ovarian cancer.
por: Reyes-Gonzalez, Jeyshka M., et al.
Publicado: (2019)

PTPN13 Participates in the Regulation of Epithelial–Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells
por: Aptecar, Leticia, et al.
Publicado: (2023)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients
por: Tassi, Renata A., et al.
Publicado: (2019)

Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response
por: Mairinger, Fabian, et al.
Publicado: (2019)

Prognostic Value of TNFR2 and STAT3 among High-Grade Serous Ovarian Cancer Survivors According to Platinum Sensitivity
por: Silva Raju, Janisha, et al.
Publicado: (2021)

Development and Validation of an Immune-Related Gene-Pair Model of High-Grade Serous Ovarian Cancer After Platinum-Based Chemotherapy
por: Lin, Jiaxing, et al.
Publicado: (2021)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023)

KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma
por: Saglam, Ozlen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ih7i3hgk0togcv9g2q78vkkv2n